Conflicts of interest This article forms part of a supplement sponsored by GlaxoSmithKline. CM Sköld has received consultancy and Advisory Board fees from Boehringer-Ingelheim/Pfizer, Novartis, Sanofi-Aventis and GlaxoSmithKline, and lecture fees from AstraZeneca, Boehringer-Ingelheim, Pfizer and GlaxoSmithKline
Remodeling in asthma and COPD – differences and similarities
Article first published online: 14 APR 2010
© 2010 Blackwell Publishing Ltd
The Clinical Respiratory Journal
Special Issue: Airway Remodelling in Asthma
Volume 4, Issue Supplement s1, pages 20–27, May 2010
How to Cite
Sköld, C. M. (2010), Remodeling in asthma and COPD – differences and similarities. The Clinical Respiratory Journal, 4: 20–27. doi: 10.1111/j.1752-699X.2010.00193.x
- Issue published online: 14 APR 2010
- Article first published online: 14 APR 2010
- Received: 16 December 2009Accepted: 3 February 2010
- chronic obstructive pulmonary disease (COPD);
- small airways
Background: Asthma and chronic obstructive pulmonary disease (COPD) are both inflammatory disorders. Diagnosis of these diseases is based upon limitation of expiratory airflow. The pathophysiological correlates to this impaired lung function are complex but they are associated with the development of structural changes in the airways and lung parenchyma. These remodeling processes differ between the two diseases. In asthma, airways obstruction is predominately located in the large airways, although recent studies indicate that inflammation and structural changes also is present in other compartments of the lungs. In COPD, remodeling of the small airways and lung parenchyma are the main correlates to the limitation of expiratory airflow. However, both asthma and COPD are heterogeneous disorders including various phenotypes and there is a considerable overlap between the two diseases.
Methods and Results: In the present review, airway remodeling in asthma and COPD will be discussed in three different compartments of the airways: large airways, small airways and lung parenchyma. Different inflammatory cells will be mentioned, as well as markers of remodeling.
Conclusion: In COPD and severe asthma, current anti-inflammatory pharmacotherapy does not restore lung function impairment fully. It is therefore recognized that research aiming to explore mechanisms of airway remodeling should be encouraged.
Please cite this paper as: Sköld CM. Remodeling in asthma and COPD – differences and similarities. Clin Respir J 2010; 4 (Suppl. 1): 20–27.